A detailed history of Joel Greenblatt (Gotham Asset Management, LLC) transactions in United Therapeutics Corp stock. As of the latest transaction made, Gotham Asset Management, LLC holds 52,058 shares of UTHR stock, worth $19.4 Million. This represents 0.2% of its overall portfolio holdings.

Number of Shares
52,058
Previous 47,593 9.38%
Holding current value
$19.4 Million
Previous $15.2 Million 23.05%
% of portfolio
0.2%
Previous 0.2%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$311.04 - $363.55 $1.39 Million - $1.62 Million
4,465 Added 9.38%
52,058 $18.7 Million
Q2 2024

Aug 14, 2024

BUY
$228.26 - $319.04 $347,868 - $486,216
1,524 Added 3.31%
47,593 $15.2 Million
Q1 2024

May 15, 2024

BUY
$210.76 - $249.51 $4.19 Million - $4.96 Million
19,863 Added 75.8%
46,069 $10.6 Million
Q4 2023

Feb 14, 2024

SELL
$214.88 - $256.94 $162,234 - $193,989
-755 Reduced 2.8%
26,206 $5.76 Million
Q3 2023

Nov 14, 2023

SELL
$211.82 - $248.24 $275,366 - $322,712
-1,300 Reduced 4.6%
26,961 $6.09 Million
Q2 2023

Aug 14, 2023

SELL
$205.19 - $232.99 $19,287 - $21,901
-94 Reduced 0.33%
28,261 $6.24 Million
Q1 2023

May 15, 2023

BUY
$212.99 - $276.17 $3.84 Million - $4.98 Million
18,045 Added 175.02%
28,355 $6.35 Million
Q4 2022

Feb 14, 2023

SELL
$205.95 - $280.43 $460,504 - $627,041
-2,236 Reduced 17.82%
10,310 $2.87 Million
Q3 2022

Nov 14, 2022

BUY
$203.3 - $244.17 $705,247 - $847,025
3,469 Added 38.22%
12,546 $2.63 Million
Q2 2022

Aug 15, 2022

BUY
$174.81 - $241.14 $295,079 - $407,044
1,688 Added 22.84%
9,077 $2.14 Million
Q1 2022

May 16, 2022

SELL
$166.16 - $213.96 $278,484 - $358,596
-1,676 Reduced 18.49%
7,389 $1.33 Million
Q4 2021

Feb 14, 2022

SELL
$184.32 - $216.08 $747,233 - $875,988
-4,054 Reduced 30.9%
9,065 $1.96 Million
Q3 2021

Nov 15, 2021

BUY
$179.86 - $214.88 $541,198 - $646,573
3,009 Added 29.76%
13,119 $2.42 Million
Q2 2021

Aug 16, 2021

SELL
$170.47 - $211.93 $1.54 Million - $1.92 Million
-9,054 Reduced 47.24%
10,110 $1.81 Million
Q1 2021

May 17, 2021

BUY
$153.94 - $174.85 $1.16 Million - $1.32 Million
7,546 Added 64.95%
19,164 $3.21 Million
Q4 2020

Feb 16, 2021

SELL
$101.87 - $151.79 $1.75 Million - $2.6 Million
-17,130 Reduced 59.59%
11,618 $1.76 Million
Q3 2020

Nov 16, 2020

SELL
$99.9 - $121.13 $526,473 - $638,355
-5,270 Reduced 15.49%
28,748 $2.9 Million
Q2 2020

Aug 13, 2020

BUY
$92.74 - $125.82 $413,434 - $560,905
4,458 Added 15.08%
34,018 $4.12 Million
Q1 2020

May 15, 2020

SELL
$79.39 - $115.35 $3.15 Million - $4.57 Million
-39,631 Reduced 57.28%
29,560 $2.8 Million
Q4 2019

Feb 14, 2020

BUY
$78.31 - $95.34 $1.69 Million - $2.06 Million
21,574 Added 45.31%
69,191 $6.09 Million
Q3 2019

Nov 14, 2019

SELL
$74.85 - $85.99 $44,610 - $51,250
-596 Reduced 1.24%
47,617 $3.8 Million
Q2 2019

Aug 14, 2019

BUY
$76.06 - $120.81 $2.73 Million - $4.33 Million
35,858 Added 290.23%
48,213 $3.76 Million
Q1 2019

May 15, 2019

SELL
$107.15 - $126.84 $1.99 Million - $2.36 Million
-18,572 Reduced 60.05%
12,355 $1.45 Million
Q4 2018

Feb 14, 2019

SELL
$101.4 - $128.73 $413,813 - $525,347
-4,081 Reduced 11.66%
30,927 $3.37 Million
Q3 2018

Nov 14, 2018

SELL
$113.81 - $129.46 $3.67 Million - $4.17 Million
-32,233 Reduced 47.94%
35,008 $4.48 Million
Q2 2018

Aug 14, 2018

SELL
$101.14 - $118.31 $1.47 Million - $1.72 Million
-14,519 Reduced 17.76%
67,241 $7.61 Million
Q1 2018

May 15, 2018

BUY
$107.21 - $151.94 $1.66 Million - $2.35 Million
15,490 Added 23.37%
81,760 $9.19 Million
Q4 2017

Feb 14, 2018

SELL
$118.58 - $151.28 $13.6 Million - $17.4 Million
-114,915 Reduced 63.42%
66,270 $9.81 Million
Q3 2017

Nov 14, 2017

BUY
$114.6 - $136.81 $20.8 Million - $24.8 Million
181,185
181,185 $21.2 Million

Others Institutions Holding UTHR

About UNITED THERAPEUTICS Corp


  • Ticker UTHR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,516,300
  • Market Cap $17B
  • Description
  • United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...
More about UTHR
Track Joel Greenblatt's Portfolio

Track Joel Greenblatt Portfolio

Follow Joel Greenblatt (Gotham Asset Management, LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gotham Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gotham Asset Management, LLC and Joel Greenblatt with notifications on news.